Company intelligence / Profile preview

Yangling Buchang Pharmaceutical

Yangling or Xi'an (region confirmed as Shaanxi Province), Shaanxi, China

Ownership: Private
Development stage: Other

Overview

The company's approved product, Yangzheng Compound Mixture, is a TCM herbal formulation approved in China for frailty syndrome, with ongoing clinical research in sleep disorders in cancer patients with Qi-Yin deficiency during chemotherapy. No publicly available data indicate the presence of non-herbal, targeted, or molecularly characterized assets.

Therapeutic areas: OncologyOther
Modalities: Herbal medicine
Industry: Biotech

Beyond the preview

Go deeper on Yangling Buchang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yangling Buchang Pharmaceutical.

Explore the full profile